Pan-cancer analysis of the potential of PEA3 subfamily genes as tumor markers.

Polyomavirus enhancer activator 3 (PEA3), an ETS transcription factor, has been documented to regulate the development and metastasis of human cancers. Nonetheless, a thorough analysis examining the relationship between the PEA3 subfamily members and tumour development, prognosis, and the tumour microenvironment (TME) across various cancer types has not yet been conducted. The expression profiles and prognostic significance of the PEA3 subfamily were evaluated using data from the GEO, TCGA, and PrognoScan databases, in conjunction with COX regression analyses and the Kaplan-Meier Plotter. Furthermore, the relationships between PEA3 subfamily expression, stemness scores, tumor microenvironments, immune subtypes, and drug susceptibility across multiple cancer types were explored. We found that ETV1, ETV4 and ETV5 are highly expressed in cancer, and their biological functions are synergistic. In the prognostic analysis of the Cancer Genome Atlas, the PEA3 subfamily genes were found to be associated with the prognosis of multiple cancers such as Lung adenocarcinoma (LUAD), Liver hepatocellular carcinoma (LIHC), etc., and marked a worse prognosis at different endpoints. In addition, it was significantly correlated with the stromal and immune scores of pan-cancer, and also significantly associated with the RNA stemness score and DNA stemness score of pan-cancer. Expression levels of the PEA3 subfamily genes correlate with immune subtypes of LIHC, LUAD, and Lung squamous cell carcinoma. We also found a variety of drugs with positive and negative associations of ETV1, ETV4 and ETV5. These findings elucidate the role of the PEA3 subfamily gene as a biomarker for carcinogenesis and cancer progression, offering valuable insights for future research into the PEA3 subfamily gene as a potential therapeutic target across various cancer types.